Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 27;14(5):514-520.
doi: 10.4240/wjgs.v14.i5.514.

Castleman disease of the pancreas mimicking pancreatic malignancy on 68Ga-DOTATATE and 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report

Affiliations
Case Reports

Castleman disease of the pancreas mimicking pancreatic malignancy on 68Ga-DOTATATE and 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report

Sheng-Lu Liu et al. World J Gastrointest Surg. .

Abstract

Background: Castleman disease is an uncommon nonclonal lymphoproliferative disorder, which frequently mimics both benign and malignant abnormalities in several regions. Depending on the number of lymph nodes or regions involved, Castleman disease (CD) varies in diagnosis, treatment and prognosis. It rarely occurs in the pancreas alone without any distinct clinical feature and tends to be confused with pancreatic paraganglioma (PGL), neuroendocrine tumors (NETs), and primary tumors, thus impeding proper diagnosis and treatment.

Case summary: A 28-year-old woman presented with a lesion on the neck of the pancreas, detected by ultrasound during a health examination. Physical examination and laboratory findings were normal. The mass showed hypervascularity on enhanced computed tomography (CT), significantly increased 18F-fluorodeoxyglucose uptake on positron emission tomography (PET)/CT, and slightly increased somatostatin receptor (SSTR) expression on 68Ga-DOTATATE PET/CT, suggesting no distant metastases and subdiagnoses such as pancreatic PGL, NET, or primary tumor. Intraoperative pathology suggested lymphatic hyperplasia, and only simple tumor resection was performed. The patient was diagnosed with the hyaline vascular variant of CD, which was confirmed by postoperative immunohistochemistry. The patient was discharged successfully, and no recurrence was observed on regular review.

Conclusion: High glucose uptake and slightly elevated SSTR expression are potentially new diagnostic features of CD of the pancreas.

Keywords: Case report; Castleman disease; Pancreatic malignancy; Pancreatic neuroendocrine tumors; Pancreatic paraganglioma; Positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Preoperative computed tomography of the abdomen. A: A plain computed tomography (CT) scan showed a hyperdense lesion measuring 3.0 cm × 2.0 cm × 2.5 cm in the neck of the pancreas; B: On enhanced CT, the lesion showed significant enhancement in the arterial phase, evenly distributed with smooth and well-defined boundaries; C: In the venous phase, the lesion was gradually washed out.
Figure 2
Figure 2
18F-fluorodeoxyglucose positron emission tomography/computed tomography showing glucose hypermetabolism in the pancreatic mass. A: Axial positron emission tomography/computed tomography (PET/CT); B: Coronal PET/CT; C: Sagittal PET/CT.
Figure 3
Figure 3
68Ga-DOTATATE positron emission tomography/computed tomography revealing slightly elevated somatostatin receptor expression on the pancreatic mass. A: Axial positron emission tomography/computed tomography (PET/CT); B: Coronal PET/CT; C: Sagittal PET/CT.
Figure 4
Figure 4
Specimen photograph and pathological photographs. A: The pancreatic mass with an intact envelope, measuring approximately 3.5 cm × 3 cm; B: Photomicrograph (hematoxylin-eosin stain) suggesting a germinal center with the classic “onionskin” appearance (magnification × 200); C: Immunohistochemistry of CD21 (magnification × 200); D: Immunohistochemistry of Ki-67 (magnification × 200).

Similar articles

Cited by

References

    1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250:1001–1005. - PubMed
    1. Bonekamp D, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics. 2011;31:1793–1807. - PubMed
    1. Huang Z, Jin T, Zhang X, Wu Z. Pancreatic mass found to be Castleman disease, a rare case report. Asian J Surg. 2020;43:767–768. - PubMed
    1. Koa B, Borja AJ, Aly M, Padmanabhan S, Tran J, Zhang V, Rojulpote C, Pierson SK, Tamakloe MA, Khor JS, Werner TJ, Fajgenbaum DC, Alavi A, Revheim ME. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging. 2021;12:35. - PMC - PubMed
    1. Verçosa AFA, Flamini MEDM, Loureiro LVM, Flamini RC. 68Ga-DOTATATE and 18F-FDG in Castleman Disease. Clin Nucl Med. 2020;45:868–870. - PubMed

Publication types